Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.110
+0.060 (2.92%)
Nov 21, 2024, 12:14 PM EST - Market open
Allogene Therapeutics Revenue
Allogene Therapeutics had revenue of $43.00K in the twelve months ending September 30, 2024, up 26.47% year-over-year. In the year 2023, Allogene Therapeutics had annual revenue of $95.00K, down -39.10%.
Revenue (ttm)
$43.00K
Revenue Growth
+26.47%
P/S Ratio
n/a
Revenue / Employee
$185
Employees
233
Market Cap
442.41M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Xeris Biopharma Holdings | 187.36M |
SIGA Technologies | 173.73M |
Pacific Biosciences of California | 173.15M |
Rigel Pharmaceuticals | 157.37M |
National Research | 144.16M |
Quanterix | 129.33M |
Aquestive Therapeutics | 58.90M |
Tango Therapeutics | 43.38M |
ALLO News
- 2 days ago - Allogene Therapeutics Announces Participation in December Investor Conferences - GlobeNewsWire
- 3 days ago - Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence - GlobeNewsWire
- 13 days ago - Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 14 days ago - Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS - GlobeNewsWire
- 16 days ago - Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 22 days ago - Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update - GlobeNewsWire
- 7 weeks ago - Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity - GuruFocus